Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2016

01-05-2016 | Brief Research Article

Bone marrow trephine biopsy involvement by lymphoma: pattern of involvement and concordance with flow cytometry, in 10 years from a single institution

Authors: M. A. Cabezas-Quintario, P. Gomez, V. Yuste-Del Pozo, A. L. Valencia-Mesa, G. Sosa, P. Ricard, A. I. Hijas-Gómez, F. Pinedo, M. Arguelles

Published in: Clinical and Translational Oncology | Issue 5/2016

Login to get access

Abstract

Purpose

To evaluate the features of bone marrow (BM) biopsy involvement by lymphoma, pattern of infiltration, morphological analysis and flow cytometry were reviewed at all lymphoma patients over a period of 10 years.

Methods/patients

413 cases were included in the study if BM biopsy slides were available. Only 356 patients had both BM trephine biopsy and flow cytometry.

Results

The most frequent subtype was diffuse large B cell (31.2 %), followed by follicular lymphoma (18.9 %). The predominant pattern was mixed (nodular-interstitial) (9.2 %). Morphological marrow infiltration was found in 138 cases, and flow cytometry identified 117 cases with BM involvement. A concordance between the two methods was detected in 305 cases (85.7 %). There was discordance in 51 cases (14.3 %): morphology positive/FC negative in 33 cases and morphology negative/FC positive in 18.

Conclusions

Flow cytometry is slightly more useful in detecting involvement when the BM is affected, but this finding is not conclusive.
Literature
1.
Dee JW, Valdivieso M, Drewinko B. Comparison of the efficacies of closed trephine needle biopsy, aspirated paraffin-embedded clot section, and smear preparation in the diagnosis of bone-marrow involvement by lymphoma. Am J Clin Pathol. 1976;65(2):183–94.CrossRefPubMed
2.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe E. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–32.CrossRefPubMedPubMedCentral
3.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SS, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC; 2008. ISBN 13 9789283224310, ISBN 10 9283224310
4.
Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555–62.CrossRefPubMed
5.
Berget E, Helgeland L, Liseth K, Løkeland T, Molven A, Vintermyr OK. Prognostic value of bone marrow involvement by clonal immunoglobulin gene rearrangements in follicular lymphoma. J Clin Pathol. 2014;67(12):1072–7.CrossRefPubMedPubMedCentral
6.
Canioni D, Brice P, Lepage E, Chababi M, Meignin V, Salles B, et al. Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d’Etude des Lymphomes Folliculaires. Br J Haematol. 2004;126:364–71.CrossRefPubMed
7.
Palacio C, Acebedo G, Navarrete M, Ruiz-Marcellan C, Sanchez C, Blanco A, et al. Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas. Haematologica. 2001;86:934–40.PubMed
8.
Arber DA, George TI. Bone marrow biopsy involvement by non-Hodgkin´s lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol. 2005;29:1549–57.CrossRefPubMed
9.
Sovani V, Harvey C, Haynes A, McMillan A, Clark D, O´Connor S. Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings. J Clin Pathol. 2014;67:389–95.CrossRefPubMed
10.
11.
Perea G, Altés A, Bellido M, Aventín A, Bordes R, Ayats R, et al. Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL). Histopathology. 2004;45:268–74.CrossRefPubMed
12.
Metadata
Title
Bone marrow trephine biopsy involvement by lymphoma: pattern of involvement and concordance with flow cytometry, in 10 years from a single institution
Authors
M. A. Cabezas-Quintario
P. Gomez
V. Yuste-Del Pozo
A. L. Valencia-Mesa
G. Sosa
P. Ricard
A. I. Hijas-Gómez
F. Pinedo
M. Arguelles
Publication date
01-05-2016
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1393-9

Other articles of this Issue 5/2016

Clinical and Translational Oncology 5/2016 Go to the issue

Research Article

Trends in lung cancer incidence by histologic subtype in the south of Spain, 1985–2012: a population-based study

Research Article

Clinical target volume in postoperative radiotherapy for gastric cancer: identification of major difficulties and controversies

Research Article

The effect of slice thickness on target and organs at risk volumes, dosimetric coverage and radiobiological impact in IMRT planning

Research Article

MicroRNA-33b inhibits tumor cell growth and is associated with prognosis in colorectal cancer patients

Research Article

Safety of bevacizumab in patients younger than 4 years of age

Research Article

The effect of EGB on proliferation of gastric carcinoma SGC7901 cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits